Table 2.
HLA Laboratory initial certification testing resultsa, by laboratory comparison and locus, T1DGC, July 4, 2009
| A (%) | B (%) | C (%) | DPA1 (%) | DPB1 (%) | DQA1 (%) | DQB1 (%) | DRB1 (%) | Total (%) | |
|---|---|---|---|---|---|---|---|---|---|
| Comparison | |||||||||
| T1DGC vs CDCb | – | 1 (97.5) | 2 (95.0) | – | – | – | – | – | 3 (99.1) |
| North American I vs T1DGC | – | – | – | – | – | 2 (95.0) | – | – | 2 (99.4) |
| North American II vs T1DGC | – | – | – | – | – | – | – | – | – |
| Asia-Pacific vs T1DGC | – | 2 (95.0) | 1 (97.5) | – | – | 5 (87.5) | – | – | 8 (97.5) |
| European vs T1DGC | – | 2 (95.0) | 1 (97.5) | – | – | – | – | – | 3 (99.1) |
| Total | – | 5 (96.9) | 4 (97.5) | – | – | 7 (95.6) | – | – | 16 (98.7) |
Allelic concordance is shown at the allele level for T1DGC consensus genotypes compared to CDC, and individual T1DGC HLA laboratories compared to the consensus. ‘–’ indicates 100% concordance. Other counts are the numbers of discordant alleles (% concordance). These results are for the second blinded initial certification testing as described in the text. Each laboratory typed 20 unrelated, mixed-ethnicity samples (40 alleles × 8 loci).
All discrepancies between T1DGC consensus and CDC are due to ambiguities, i.e., identity within the tested exons.